Summary
Plasma cholesterol, triglycerides, HDL2-cholesterol, and HDL3-cholesterol were studied in 18 patients with Type 2 diabetes. Prior to entering the clinical trial, the study subjects were in stable control under a fixed mixture of 20% regular and 80% NPH (isophane) biosynthetic human insulin twice daily. The patients were randomized to treatment with either biosynthetic human proinsulin or biosynthetic human NPH insulin (controls) twice daily. Glucose control was kept constant in both groups throughout the study. Of the nine patients treated with proinsulin, eight exhibited a decrease of plasma triglycerides (median decrease by 0.13 mmol/l). In contrast, all nine controls showed a rise (median increase by 0.69 mmol/l) of plasma triglycerides (p<0.001). In keeping with the fall of plasma triglycerides, HDL2-cholesterol rose in all but one proinsulin-treated patients. Both treatment modalities reduced HDL3-cholesterol with a median decrease of 0.20 mmol/l (p<0.01) with proinsulin and 0.26 mmol/l with NPH insulin (p<0.05).
We conclude that human proinsulin is able to reduce plasma triglycerides and to increase HDL2-cholesterol in the majority of patients with Type 2 diabetes and thus appears to alter favourably risk factors for coronary heart disease.
Similar content being viewed by others
Abbreviations
- HDL:
-
High density lipoproteins
- NPH insulin:
-
Neutral Protamine Hagedorn (isophane) insulin
References
Bennion LJ, Grundy SM (1977) Effects of diabetes mellitus on cholesterol metabolism in man. N Engl J Med 296:1365–1371
Drexel H, Dzien A, Huter O, Lisch H-J, Braunsteiner H (1987) Variability of the fructosamine assay in pregnancy. Diabetologia 30:972 (Letter)
Eder HA, Bergmann M (1983) Metabolism of plasma lipids and lipoproteins. In: Ellenberg M, Rifkin H (eds) Diabetes mellitus, theory and practice, Medical Examination Publishing, New York, pp 61–76
Glauber HS, Henry RR, Wallace P, Frank BH, Galloway JA, Cohen RM, Olefsky JM (1987) The effects of biosynthetic human proinsulin on carbohydrate metabolism in noninsulin-dependent diabetes mellitus. N Engl J Med 316:443–449
Nathan DM, Avezzano E, Palmer JL (1982) Rapid method for eliminating labile glycosylated hemoglobin from the assay for hemoglobin A1. Clin Chem 28:512–515
Nestel PJ (1980) Cholesterol metabolism in diabetes mellitus. In: Waldhäusl WK (ed) Diabetes 1979. Elsevier, Amsterdam, pp 586–589
Nikkilä EA, Huttunen JK, Ehnholm Ch (1977) Postheparin plasma lipoprotein lipase and hepatic lipase in diabetes mellitus. Diabetes 26:11–21
Patsch JR, Gotto AM, Olivecrona T, Eisenberg S (1978) Formation of high-density-lipoprotein2-like particles during lipolysis of very low density lipoproteins in vitro. Proc Natl Acad Sci (USA) 75:4519–4523
Patsch JR, Prasad S, Gotto AM, Patsch W (1987) High Density Lipoprotein2. Relationship of the plasma levels of this lipoprotein species to its composition, to the magnitude of postprandial lipemia, and to the activities of lipoprotein lipase and hepatic lipase. J Clin Invest 80:341–347
Saudek CD, Brach EL (1978) Cholesterol metabolism in diabetes. The effect of diabetic control on sterol balance. Diabetes 27:1059–1064
Warnick GR, Benderson J, Albers JJ (1982) Quantitation of high-density-lipoprotein subclasses after separation by dextran sulfate and Mg2+ precipitation. Clin Chem 28:1574 (Abstract)
Wilcoxon F, Kotti S, Wilcox A (1963) Critical values and probability levels for the Wilcoxon Rank Sum Test and the Wilcoxon Signed Rank Test. Lederle Laboratories, Division Amer. Cyanamid Company, Pearl River, New York
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Drexel, H., Hopferwieser, T., Braunsteiner, H. et al. Effects of biosynthetic human proinsulin on plasma lipids in type 2 diabetes mellitus. Klin Wochenschr 66, 1171–1174 (1988). https://doi.org/10.1007/BF01727664
Received:
Revised:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF01727664